Tag: healthcare
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just $27.1 million of year-end cash leave little room for delay before clinical proof arrives.
Lantheus Stock Analysis: Buy or Sell? Valuation, Margins & Growth
Lantheus (LNTH) is rated Hold because strong cash generation and a low-debt balance sheet are offset by uneven quarterly revenue growth. Its 24.1x trailing P/E and 16.9x EV/EBITDA leave less room for disappointment.
Nutex Health Stock Analysis: Buy or Sell? Free Cash Flow, Valuation, Reimbursement Risk
Nutex Health Inc. (NUTX) is rated Buy in this stock analysis because it is already turning revenue into strong free cash flow, with a 15.6% FCF yield and 19.2% FCF margin. The key risk is reimbursement and arbitration exposure, which could pressure earnings if disputed claims stay elevated.
Stereotaxis Stock Analysis: Buy or Sell? Cash Burn, Revenue, Valuation & Margins
Stereotaxis (STXS) is rated Sell as uneven revenue and ongoing cash burn outweigh the platform’s gross-margin potential. A 4.6x EV/revenue multiple looks demanding while levered free cash flow remains negative, keeping dilution and execution risk front and center.
Clover Health Stock Analysis: Buy or Sell? Valuation & Margins, Cash Flow
Clover Health Investments Corp. (CLOV) is rated Hold after its first profitable quarter, but trailing margins and free cash flow still lag. The business needs sustained revenue and EBITDA improvement before the new inflection looks durable.
GeneDx Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margins
GeneDx Holdings Corp. (WGS) is rated Sell as the market prices in a clean earnings recovery that cash flow and margin trends do not yet support. Revenue growth is improving, but positive free cash flow remains elusive and reimbursement pressure could delay a rerating.
Cigna Group Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margin
The Cigna Group (CI) is rated Hold as its durable cash generation offsets a post-divestiture earnings base that still needs to prove itself. The 9.0% FCF yield and 1.72x net debt to EBITDA support the stock, but margin improvement remains the key test.
Intuitive Surgical Stock Analysis: Valuation, Procedure Growth, China Risk & Cash Flow
Intuitive Surgical (ISRG) earns a HOLD rating as its dominant installed base and recurring revenue continue to support strong cash generation. However, the stock already prices in durable execution at a rich valuation, with China tender delays and pricing pressure clouding near-term upside.
Abbott Laboratories Stock Analysis: Valuation, Margins, Debt & Growth
Abbott Laboratories (ABT) is rated Hold as its diversified healthcare platform supports stability, but valuation and execution concerns cap near-term upside. Q1 2026 revenue and EBIT weakened sequentially, while debt tied to acquisition financing could pressure flexibility.